When responding to outbreaks of viral disease, public health officials are often challenged...
- Vaccine development: the need for speed
- Lack of CMO availability threatens cell and gene therapy development
- Novaliq’s NovaTears+Omega-3 represents the first-in-class omega-3-containing eye drop for evaporative dry eye
- Surprisingly good Phase II results for ibudilast in progressive MS
- Tenapanor likely to makes waves in IBS-C space
B&W Tek NanoRam Handheld Raman Spectrometer
The NanoRam is a state-of-the-art handheld Ramen instrument for non-destructive identification and verification of incoming raw materials such as active pharmaceutical ingredients (API), excipients, and intermediates.
Paradigm Shift Regarding API and Formulation Components
This whitepaper will provide an introduction to high-purity carbohydrates often used for applications such as stabilisation, modulation, and cryopreservation, comparing the old paradigm that formulation components are inactive ingredients with limited functionality with the new paradigm, which suggests these components play a significant role in therapeutic stability, quality, potency, immunogenicity, and bioavailability.
Adcetris® for the Treatment of Relapsed or Refractory Hodgkin’s Lymphoma
Adcetris® (brentuximab vedotin) is a treatment for relapsed or refractory (r/r) Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL) that was developed by Seattle Genetics and Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical.
Tradjenta Indicated for the Treatment of Type II Diabetes
Linagliptin (BI-1356), which is being marketed under the trade name Tradjenta®, is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor drug for the treatment of type 2 diabetes.
Blincyto® (blinatumomab) for the Treatment of B-cell Precursor Acute Lymphoblastic Leukaemia
Blincyto® (blinatumomab) is a monoclonal antibody indicated as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL) in adults and children.
Characterising Liposomes using Multi-Angle DLS
Liposomes are nowadays frequently used as drug delivery systems, and as such requires that they are well characterised for manufacturing and batch release. This characterisation includes their size and size distribution.
JYNARQUE™ (tolvaptan) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
JYNARQUE™ (tolvaptan) is indicated for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.